Thursday , August 17 2017
Home / Business News

Business News

Takeda and Stanford University Partner to Drive Therapeutic Discoveries

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE: 4502) today announced a collaboration with Stanford University to form the Stanford Alliance for Innovative Medicines (Stanford AIM), which will help transform novel Stanford research into next-generation treatments for diseases. Through this unique collaboration, Takeda and Stanford will identify projects on the path …

Read More »

Dermira Enters into Agreement for Global Rights to Roche’s IL-13 Drug Lebrikizumab

MENLO PARK, Calif., Aug. 08, 2017 (GLOBE NEWSWIRE) — Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that it has entered into a licensing agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc., a …

Read More »

Biosimilars Forum Applauds Senator Passage of the FDA Reauthorization Act

Washington, D.C. (August 3, 2017) – Today, the Biosimilars Forum issued the following statement on passage of the Food and Drug Administration Reauthorization Act (FDARA): “The Biosimilars Forum applauds Senate passage of the FDA Reauthorization Act. This legislation provides the agency with the resources it needs to effectively and efficiently …

Read More »

Mallinckrodt to Acquire InfaCare Pharmaceutical

STAINES-UPON-THAMES, United Kingdom, Aug. 4, 2017 /PR Newswire/ — Mallinckrodt plc (NYSE: MNK), a leading global specialty pharmaceutical company, and InfaCare Pharmaceutical Corporation today announced that they have entered into an agreement under which Mallinckrodt will acquire InfaCare, a privately held specialty pharmaceutical company focused on development and commercialization of …

Read More »

Bristol-Myers Squibb to Acquire IFM Therapeutics, Strengthening its Oncology Pipeline Focus on Innate Immunity

NEW YORK & BOSTON–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) and IFM Therapeutics (IFM) announced today that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire all of the outstanding capital stock of IFM Therapeutics, a venture-backed biotech company focused on developing therapies that modulate novel targets in …

Read More »

Takeda and Molecular Templates Collaborate for Next-Generation Oncology Therapies

OSAKA, Japan & AUSTIN, Texas–(BUSINESS WIRE)–Takeda Pharmaceutical Company Limited (TSE: 4502) and Molecular Templates, Inc. today announced a collaboration agreement for oncology drug discovery programs. The collaboration will apply Molecular Templates’ engineered toxin bodies (ETB) technology platform to potential therapeutic targets provided by Takeda through a joint scientific committee of …

Read More »

LabCorp to Acquire Specialty CRO Chiltern for $1.2 Billion in Cash

BURLINGTON, N.C. & WILMINGTON, N.C. & LONDON–(BUSINESS WIRE)–LabCorp® (NYSE:LH), a leading global life sciences company, and Chiltern, a specialty CRO, announced today that LabCorp will acquire Chiltern pursuant to a definitive agreement with Chiltern’s shareholders in an all-cash transaction valued at approximately $1.2 billion. Once the transaction is complete, Chiltern …

Read More »

Merck and AstraZeneca Enter Strategic Oncology Collaboration

ENILWORTH, N.J.–(BUSINESS WIRE)–AstraZeneca and Merck & Co., Inc., (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that they have entered a global strategic oncology collaboration to co-develop and co-commercialize AstraZeneca’s LYNPARZA (olaparib) for multiple cancer types. LYNPARZA is an innovative, first-in-class oral poly ADP …

Read More »

Astellas Announces Wind-Down of Agensys Research Operations

TOKYO, July 26, 2017 /PRNewswire/ — Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) announced today that it is winding down its Agensys research operations in Santa Monica, California, USA, to further refine its oncology strategy by expanding its investment in the research in new technologies and modalities and reducing its focus …

Read More »

Servier Licenses GLPG1972 in Osteoarthritis from Galapagos

28 July 2017 – As a result of their research collaboration, Servier announces today that it has exercised its option to develop novel osteoarthritis molecule GLPG1972/S201086 from Galapagos NV (Euronext/NASDAQ: GLPG), thus obtaining global commercial rights outside the U.S. Osteoarthritis (OA) is a highly prevalent and disabling pathology, considered as …

Read More »